[1] |
SIEGEL R L, MILLER K D, JEMAL A. Cancer statistics, 2020[J]. CA Cancer J Clin, 2020, 70(1): 7-30.
doi: 10.3322/caac.v70.1
|
[2] |
江泽飞, 许凤锐. 乳腺癌精准治疗:20年探索历程[J]. 中国实用外科杂志, 2020, 40(1): 83-88.
|
|
JIANG Z F, XU F R. Precise treatment of breast cancer: two decades of exploration[J]. Chin J Pract Surg, 2020, 40(1): 83-88.
|
[3] |
袁洋, 江泽飞. 再议乳腺癌内分泌治疗热点问题[J]. 中华医学杂志, 2023, 103(34): 2647-2651.
|
|
YUAN Y, JIANG Z F. Rediscussion on hot issues of endocrine therapy for breast cancer[J]. Natl Med J China, 2023, 103(34): 2647-2651.
|
[4] |
ZHANG P, ZHANG Q Y, TONG Z S, et al. Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2023, 24(6): 646-657.
doi: 10.1016/S1470-2045(23)00172-9
|
[5] |
YUAN Y, ZHANG S H, WANG T, et al. Efficacy and safety of abemaciclib-based therapy versus tucidinostat-based therapy after progression on palbociclib in patients with HR+ HER2- metastatic breast cancer[J]. Transl Breast Cancer Res, 2023, 4: 10.
doi: 10.21037/tbcr
|
[6] |
ANDRAHENNADI S, SAMI A, MANNA, et al. Current landscape of targeted therapy in hormone receptor-positive and HER2-negative breast cancer[J]. Curr Oncol, 2021, 28(3): 1803-1822.
doi: 10.3390/curroncol28030168
pmid: 34064867
|
[7] |
ASHAI N, SWAIN S M. Post-CDK 4/6 inhibitor therapy: current agents and novel targets[J]. Cancers, 2023, 15(6): 1855.
doi: 10.3390/cancers15061855
|
[8] |
TURNER N C, OLIVEIRA M, HOWELL S J, et al. Capivasertib in hormone receptor-positive advanced breast cancer[J]. N Engl J Med, 2023, 388(22): 2058-2070.
doi: 10.1056/NEJMoa2214131
|
[9] |
LI Y, LI W, GONG C C, et al. A multicenter analysis of treatment patterns and clinical outcomes of subsequent therapies after progression on palbociclib in HR+ /HER2- metastatic breast cancer[J]. Ther Adv Med Oncol, 2021, 13: 17588359211022890.
|
[10] |
MODI S N, JACOT W, YAMASHITA T, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer[J]. N Engl J Med, 2022, 387(1): 9-20.
doi: 10.1056/NEJMoa2203690
|
[11] |
中国临床肿瘤学会指南工作委员会组织. 中国临床肿瘤学会(CSCO)乳腺癌诊疗指南-2023[M]. 北京: 人民卫生出版社, 2023.
|
[12] |
冀辰辰, 李健斌, 江泽飞. HER2阳性乳腺癌分层治疗新策略[J]. 中国肿瘤临床, 2022, 49(22): 1147-1150.
|
|
JI C C, LI J B, JIANG Z F. New strategy for stratified treatment of HER2-positive breast cancer[J]. Chin J Clin Oncol, 2022, 49(22): 1147-1150.
|
[13] |
ARPINO G, DE LA HABA RODRÍGUEZ J, FERRERO J M, et al. Pertuzumab, trastuzumab, and an aromatase inhibitor for HER2-positive and hormone receptor-positive metastatic or locally advanced breast cancer: PERTAIN final analysis[J]. Clin Cancer Res, 2023, 29(8): 1468-1476.
doi: 10.1158/1078-0432.CCR-22-1092
|
[14] |
MA F, YAN M, LI W, et al. Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial[J]. BMJ, 2023, 383: e076065.
|
[15] |
HURVITZ S A, HEGG R, CHUNG W P, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial[J]. Lancet, 2023, 401(10371): 105-117.
doi: 10.1016/S0140-6736(22)02420-5
|
[16] |
LI J B, JIANG Z F. Antibody drug conjugates in breast cancer in China: highlights, challenges, and prospects[J]. Cancer, 2023. Online ahead of print.
|
[17] |
DARLIX A, LOUVEL G, FRAISSE J, et al. Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort[J]. Br J Cancer, 2019, 121(12): 991-1000.
doi: 10.1038/s41416-019-0619-y
|
[18] |
YAN M, OUYANG Q C, SUN T, et al. Pyrotinib plus capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases (PERMEATE): a multicentre, single-arm, two-cohort, phase 2 trial[J]. Lancet Oncol, 2022, 23(3): 353-361.
doi: 10.1016/S1470-2045(21)00716-6
pmid: 35085506
|
[19] |
YANG Z Z, MENG J, MEI X, et al. Brain radiotherapy with pyrotinib and capecitabine in patients with ERBB2-positive advanced breast cancer and brain metastases: a non-randomized phase 2 trial[J]. JAMA Oncol, 2024: e235791.
|
[20] |
SCHMID P, RUGO H S, ADAMS S, et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2020, 21(1): 44-59.
doi: S1470-2045(19)30689-8
pmid: 31786121
|
[21] |
MILES D, GLIGOROV J, ANDRÉ F, et al. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase Ⅲ trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer[J]. Ann Oncol, 2021, 32(8): 994-1004.
doi: 10.1016/j.annonc.2021.05.801
|
[22] |
CORTES J, CESCON D W, RUGO H S, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial[J]. Lancet, 2020, 396(10265): 1817-1828.
doi: 10.1016/S0140-6736(20)32531-9
pmid: 33278935
|
[23] |
JIANG Z F, OUYANG Q C, SUN T, et al. Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial[J]. Nat Med, 2024, 30(1): 249-256.
doi: 10.1038/s41591-023-02677-x
pmid: 38191615
|
[24] |
SCHMID P, WYSOCKI P J, MA C X, et al. Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): updated results from BEGONIA, a phase Ⅰb/Ⅱ study[J]. Ann Oncol, 2023, 34: S337.
|
[25] |
FAN L, WANG Z H, MA L X, et al. Optimising first-line subtyping-based therapy in triple-negative breast cancer (FUTURE-SUPER): a multi-cohort, randomised, phase 2 trial[J]. Lancet Oncol, 2024, 25(2): 184-197.
doi: 10.1016/S1470-2045(23)00579-X
|
[26] |
DING J H, XIAO Y, YANG F, et al. Guanosine diphosphate-mannose suppresses homologous recombination repair and potentiates antitumor immunity in triple-negative breast cancer[J]. Sci Transl Med, 2024, 16(728): eadg7740.
doi: 10.1126/scitranslmed.adg7740
|
[27] |
张会强, 江泽飞. 2022年改变晚期乳腺癌临床实践的重要研究[J]. 中国癌症杂志, 2023, 33(2): 110-116.
doi: 10.19401/j.cnki.1007-3639.2023.02.003
|
|
ZHANG H Q, JIANG Z F. Key clinical studies on changing clinical practice of advanced breast cancer in 2022[J]. China Oncol, 2023, 33(2): 110-116.
|